The Global Impact of the Mectizan Donation Program

One of the most significant chapters in the history of ivermectin is the establishment of the Mectizan Donation Program. Launched by Merck in 1987, the programme committed to providing ivermectin free of charge for as long as needed to control and eliminate river blindness (onchocerciasis).

Working in partnership with the World Health Organization, national governments, non-governmental organisations, and endemic communities, the programme has distributed billions of treatments over several decades. This sustained effort has led to a dramatic reduction in the burden of onchocerciasis in many parts of Africa and the Americas.

In addition to onchocerciasis, ivermectin has played an important role in programmes targeting lymphatic filariasis. In many settings, it is used in combination with other medicines as part of mass drug administration campaigns aimed at eliminating the disease as a public health problem.

The combination of large-scale distribution, community participation, and long-term commitment has made the Mectizan Donation Program one of the largest and most enduring drug donation initiatives in history. It stands as a notable example of successful public-private partnership.

The programme demonstrates how scientific discovery, when supported by sustained institutional commitment and international collaboration, can deliver lasting improvements in global health, particularly for populations affected by neglected tropical diseases.